02:12 PM EDT, 10/14/2025 (MT Newswires) -- Xencor ( XNCR ) shares fell nearly 7% in recent Tuesday trading after the company said it became aware that an investment bank had circulated its own takeaways from an abstract accepted for presentation at an upcoming scientific conference, even though the abstract has not yet been made public.

The company said the abstract was a placeholder submission based on an earlier data cut from its ongoing phase 1 trial of XmAb819 in patients with advanced clear cell renal cell carcinoma, a type of kidney cancer. It contained only a high-level safety summary across all dosing groups.

No new efficacy data were included beyond what Xencor ( XNCR ) had already disclosed during a public webcast in September 2024. The company said the full abstract will be released at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Oct. 22.

Price: 13.00, Change: -0.97, Percent Change: -6.91